The serum concentration of Paricalcitol can be increased when it is combined with Palbociclib. The metabolism of Paricalcitol can be decreased when combined with Fluvoxamine. The metabolism of Paricalcitol can be increased when combined with Phenobarbital. The risk or severity of adverse effects can be increased when Paricalcitol is combined with Calcipotriol. The serum concentration of Paricalcitol can be increased when it is combined with Indinavir. The metabolism of Paricalcitol can be decreased when combined with Diltiazem. Chlorothiazide may increase the hypercalcemic activities of Paricalcitol. The serum concentration of Paricalcitol can be increased when it is combined with Idelalisib. The serum concentration of Paricalcitol can be decreased when it is combined with Mineral oil. The serum concentration of Paricalcitol can be increased when it is combined with Ketoconazole. The metabolism of Paricalcitol can be increased when combined with Rifapentine. The serum concentration of Paricalcitol can be increased when it is combined with Telaprevir. The metabolism of Paricalcitol can be increased when combined with Pentobarbital. The metabolism of Paricalcitol can be decreased when combined with Delavirdine. Paricalcitol may increase the arrhythmogenic activities of Ouabain. Quinethazone may increase the hypercalcemic activities of Paricalcitol. The serum concentration of Paricalcitol can be increased when it is combined with Boceprevir. The risk or severity of adverse effects can be increased when Calcium Citrate is combined with Paricalcitol. The metabolism of Paricalcitol can be increased when combined with Lumacaftor. The serum concentration of Paricalcitol can be decreased when it is combined with Colesevelam. The serum concentration of Paricalcitol can be decreased when it is combined with Enzalutamide. The risk or severity of adverse effects can be increased when Doxercalciferol is combined with Paricalcitol. Paricalcitol may increase the arrhythmogenic activities of Digoxin Immune Fab (Ovine). Cyclopenthiazide may increase the hypercalcemic activities of Paricalcitol. The metabolism of Paricalcitol can be decreased when combined with Dronedarone. The serum concentration of Paricalcitol can be increased when it is combined with Saquinavir. Paricalcitol may increase the arrhythmogenic activities of Oleandrin. The serum concentration of Paricalcitol can be increased when it is combined with Darunavir. The risk or severity of adverse effects can be increased when Calcium Acetate is combined with Paricalcitol. The serum concentration of Paricalcitol can be increased when it is combined with Voriconazole. The serum concentration of Paricalcitol can be increased when it is combined with Mifepristone. The metabolism of Paricalcitol can be decreased when combined with Bortezomib. The serum concentration of Aluminum hydroxide can be increased when it is combined with Paricalcitol. The risk or severity of adverse effects can be increased when Calcium glubionate is combined with Paricalcitol. The metabolism of Paricalcitol can be decreased when combined with Rucaparib. Paricalcitol may increase the arrhythmogenic activities of Proscillaridin. The risk or severity of adverse effects can be increased when Paricalcitol is combined with Calcidiol. The metabolism of Paricalcitol can be decreased when combined with Olaparib. The serum concentration of Sucralfate can be increased when it is combined with Paricalcitol. Indapamide may increase the hypercalcemic activities of Paricalcitol. The metabolism of Paricalcitol can be decreased when combined with Cyclosporine. The serum concentration of Conivaptan can be increased when it is combined with Paricalcitol. The serum concentration of Paricalcitol can be increased when it is combined with Luliconazole. The serum concentration of Paricalcitol can be decreased when it is combined with Dabrafenib. The serum concentration of Paricalcitol can be increased when it is combined with Osimertinib. The metabolism of Paricalcitol can be decreased when combined with Clemastine. The serum concentration of Paricalcitol can be increased when it is combined with Simeprevir. Hydrochlorothiazide may increase the hypercalcemic activities of Paricalcitol. The metabolism of Paricalcitol can be decreased when combined with Dihydroergotamine. The serum concentration of Paricalcitol can be decreased when it is combined with Orlistat. The metabolism of Paricalcitol can be increased when combined with Fosphenytoin. The metabolism of Paricalcitol can be decreased when combined with Fosamprenavir. The metabolism of Paricalcitol can be decreased when combined with Doxycycline. The risk or severity of adverse effects can be increased when Casein is combined with Paricalcitol. The therapeutic efficacy of Paricalcitol can be decreased when used in combination with Sarilumab. The metabolism of Paricalcitol can be decreased when combined with Isradipine. The serum concentration of Paricalcitol can be decreased when it is combined with Cholestyramine. The risk or severity of adverse effects can be increased when Calcium Chloride is combined with Paricalcitol. The metabolism of Paricalcitol can be decreased when combined with Ranolazine. The metabolism of Paricalcitol can be decreased when combined with Ticlopidine. The serum concentration of Paricalcitol can be increased when it is combined with Nelfinavir. The metabolism of Paricalcitol can be decreased when combined with Fluconazole. The serum concentration of Paricalcitol can be increased when it is combined with Clarithromycin. The serum concentration of Paricalcitol can be decreased when it is combined with Vemurafenib. The metabolism of Paricalcitol can be decreased when combined with Nilotinib. The metabolism of Paricalcitol can be increased when combined with Primidone. The serum concentration of Paricalcitol can be increased when it is combined with Fosaprepitant. The risk or severity of adverse effects can be increased when Paricalcitol is combined with Digoxin. Danazol may increase the hypercalcemic activities of Paricalcitol. The metabolism of Paricalcitol can be increased when combined with Rifampicin. The risk or severity of adverse effects can be increased when Paricalcitol is combined with Ergocalciferol. Methyclothiazide may increase the hypercalcemic activities of Paricalcitol. The metabolism of Paricalcitol can be decreased when combined with Venlafaxine. The serum concentration of Paricalcitol can be decreased when it is combined with Bosentan. The serum concentration of Paricalcitol can be increased when it is combined with Lopinavir. The metabolism of Paricalcitol can be decreased when combined with Erythromycin. The risk or severity of adverse effects can be increased when Calcium gluconate is combined with Paricalcitol. The serum concentration of Paricalcitol can be increased when it is combined with Posaconazole. The risk or severity of adverse effects can be increased when Calcium Gluceptate is combined with Paricalcitol. The metabolism of Paricalcitol can be decreased when combined with Sulfisoxazole. Trichlormethiazide may increase the hypercalcemic activities of Paricalcitol. The serum concentration of Paricalcitol can be increased when it is combined with Dasatinib. The serum concentration of Paricalcitol can be increased when it is combined with Aprepitant. The risk or severity of adverse effects can be increased when Calcium Phosphate is combined with Paricalcitol. The metabolism of Paricalcitol can be decreased when combined with Sildenafil. The serum concentration of Paricalcitol can be decreased when it is combined with Mitotane. The serum concentration of Paricalcitol can be increased when it is combined with Amiodarone. The serum concentration of Paricalcitol can be increased when it is combined with Itraconazole. Bendroflumethiazide may increase the hypercalcemic activities of Paricalcitol. Polythiazide may increase the hypercalcemic activities of Paricalcitol. The risk or severity of adverse effects can be increased when Paricalcitol is combined with Dihydrotachysterol. The metabolism of Paricalcitol can be decreased when combined with Verapamil. The serum concentration of Paricalcitol can be decreased when it is combined with Colestipol. The metabolism of Paricalcitol can be decreased when combined with Lovastatin. Paricalcitol may increase the arrhythmogenic activities of Acetyldigitoxin. Chlorthalidone may increase the hypercalcemic activities of Paricalcitol. Metolazone may increase the hypercalcemic activities of Paricalcitol. The serum concentration of Paricalcitol can be decreased when it is combined with Deferasirox. The serum concentration of Paricalcitol can be decreased when it is combined with St. John's Wort. The metabolism of Paricalcitol can be increased when combined with Phenytoin. The serum concentration of Paricalcitol can be increased when it is combined with Telithromycin. The metabolism of Paricalcitol can be decreased when combined with Crizotinib. Hydroflumethiazide may increase the hypercalcemic activities of Paricalcitol. The serum concentration of Paricalcitol can be decreased when it is combined with Siltuximab. Paricalcitol may increase the arrhythmogenic activities of Digitoxin. The serum concentration of Paricalcitol can be increased when it is combined with Atazanavir. The metabolism of Paricalcitol can be decreased when combined with Isavuconazonium. The metabolism of Paricalcitol can be increased when combined with Carbamazepine. The serum concentration of Paricalcitol can be increased when it is combined with Ceritinib. The metabolism of Paricalcitol can be decreased when combined with Ziprasidone. The serum concentration of Paricalcitol can be increased when it is combined with Stiripentol. The risk or severity of adverse effects can be increased when Calcium lactate is combined with Paricalcitol. The metabolism of Paricalcitol can be increased when combined with Nevirapine. The serum concentration of Paricalcitol can be increased when it is combined with Fusidic Acid. The metabolism of Paricalcitol can be decreased when combined with Imatinib. The serum concentration of Paricalcitol can be increased when it is combined with Nefazodone. The serum concentration of Paricalcitol can be increased when it is combined with Cobicistat. The serum concentration of Paricalcitol can be increased when it is combined with Netupitant. The metabolism of Paricalcitol can be decreased when combined with Atomoxetine. The metabolism of Paricalcitol can be decreased when combined with Clotrimazole. The metabolism of Paricalcitol can be increased when combined with Rifabutin. The serum concentration of Paricalcitol can be decreased when it is combined with Tocilizumab. The serum concentration of Paricalcitol can be increased when it is combined with Ivacaftor. Paricalcitol may increase the arrhythmogenic activities of Deslanoside.